Cited by 295Cardiac Ischemia and ReperfusionPeroxisome Proliferator-Activated ReceptorsCardiac Fibrosis and Remodeling

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

In Vivo Myocardial Protection From Ischemia/Reperfusion Injury by the Peroxisome Proliferator–Activated Receptor-γ Agonist Rosiglitazone

Yue, Tian-li, Chen, Jun, Bao, Weike, Narayanan, Padma K., Bril, Antoine, Jiang, Wen, Lysko, Paul G., Gu, Juan-Li, Boyce, Rogely, Zimmerman, Dawn M., Hart, Timothy K., Buckingham, Robin E., Ohlstein, Eliot H.·2001·Circulation

DOI 10.1161/hc4601.099403

Open this paper in CoChat — free account

Abstract

BackgroundDiabetes is associated with increased risk of mortality as a consequence of acute myocardial infarction. This study determined whether rosiglitazone (ROSI) could reduce myocardial infarction after ischemia/reperfusion injury. Methods and ResultsMale Lewis rats were anesthetized, and the left anterior descending coronary artery was ligated for 30 minutes. After reperfusion for 24 hours, the ischemic and infarct sizes were determined. ROSI at 1 and 3 mg/kg IV reduced infarct size by 30% and 37%, respectively (P<0.01 versus vehicle). Pretreatment with ROSI (3 mg · kg−1· d−1 PO) for 7 days also reduced infarct size by 24% (P<0.01). ROSI also improved ischemia/reperfusion-induced myocardial contractile dysfunction. Left ventricular systolic pressure and positive and negative maximal values of the first derivative of left ventricular pressure (dP/dt) were significantly improved in ROSI-treated rats. ROSI reduced the accumulation of neutrophils and macrophages in the ischemic heart by 40% and 43%, respectively (P<0.01). Ischemia/reperfusion induced upregulation of CD11b/CD18 and downregulation of L-selectin on neutrophils and monocytes; these effects were significantly attenuated in ROSI-treated animals. Likewise, intercellular adhesion molecule-1 expression in ischemic hearts was markedly diminished by ROSI, as was the ischemia/reperfusion-stimulated upregulation of monocyte chemoattractant protein-1. ConclusionsROSI reduced myocardial infarction and improved contractile dysfunction caused by ischemia/reperfusion injury. The cardioprotective effect of ROSI was most likely due to inhibition of the inflammatory response.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1161/hc4601.099403

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation
Chawla, A., Barak, Y., Nagy, L., Liao, D., Tontonoz, P., & Evans, R. M. (2001) · Nature Medicine · doi:10.1038/83336 · Cited by 1,069
Myocardial Cell Death in Human Diabetes
Frustaci, A., Kajstura, J., Chimenti, C., Jakoniuk, I., Leri, A., Maseri, A., Nadal-Ginard, B., & Anversa, P. (2000) · Circulation Research · doi:10.1161/01.res.87.12.1123 · Cited by 796
A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response
Su, C. G., Wen, X., Bailey, S. T., Jiang, W. G., Rangwala, S. M., Keilbaugh, S. A., Flanigan, A., Murthy, S., Lazar, M. A., & Wu, G. D. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7145 · Cited by 769
Self-citation
The role of neutrophils in myocardial ischemia–reperfusion injury
Jordan, J. E. (1999) · Cardiovascular Research · doi:10.1016/s0008-6363(99)00187-x · Cited by 645
The role of PPAR-γ in macrophage differentiation and cholesterol uptake
Moore, K. J., Rosen, E. D., Fitzgerald, M. L., Randow, F., Andersson, L. P., Altshuler, D., Milstone, D. S., Mortensen, R. M., Spiegelman, B. M., & Freeman, M. W. (2001) · Nature Medicine · doi:10.1038/83328 · Cited by 518
Cardioprotective effect of insulin-like growth factor I in myocardial ischemia followed by reperfusion.
Buerke, M., Murohara, T., Skurk, C., Nuss, C., Tomaselli, K. J., & Lefer, A. M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.8031 · Cited by 394
Peroxisome proliferator‐activated receptors in the cardiovascular system
Bishop‐Bailey, D. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703149 · Cited by 365
Mechanisms of myocardial reperfusion injury
Park, J. L., & Lucchesi, B. R. (1999) · The Annals of Thoracic Surgery · doi:10.1016/s0003-4975(99)01073-5 · Cited by 338
The peroxisome proliferator-activated receptorγ (PPARγ) as a regulator of monocyte/macrophage function
Ricote, M., Huang, J. T., Welch, J. S., & Glass, C. K. (1999) · Journal of Leukocyte Biology · doi:10.1002/jlb.66.5.733 · Cited by 306
Mechanisms Determining Course and Outcome of Diabetic Patients Who Have Had Acute Myocardial Infarction
Aronson, D., Rayfield, E. J., & Chesebro, J. H. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-126-4-199702150-00006 · Cited by 304

Flagged first, then by citations

Show all 32 references

Research works printed but not linked: 4

10.1161/circ.102.11.1315 · DOI
10.1161/res.87.7.596 · DOI
10.1161/circ.101.10.1165 · DOI
10.1161/res.87.6.516 · DOI

Sorted by citations

Myocardial Fatty Acid Metabolism in Health and Disease
Lopaschuk, G. D., Ussher, J. R., Folmes, C. D. L., Jaswal, J. S., & Stanley, W. C. (2010) · Physiological Reviews · doi:10.1152/physrev.00015.2009 · Cited by 2,228
Inflammatory Cytokines and Postmyocardial Infarction Remodeling
Nian, M., Lee, P. C., Khaper, N., & Liu, P. J. (2004) · Circulation Research · doi:10.1161/01.res.0000130526.20854.fa · Cited by 1,031
PPAR control of metabolism and cardiovascular functions
Montaigne, D., Butruille, L., & Staels, B. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00569-6 · Cited by 981
Effect of Rosiglitazone Treatment on Nontraditional Markers of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus
Haffner, S. M., Greenberg, A. S., Weston, W. M., Chen, H., Williams, K., & Freed, M. I. (2002) · Circulation · doi:10.1161/01.cir.0000025403.20953.23 · Cited by 881
Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure
Nesto, R. W., Bell, D. S. H., Bonow, R. O., Fonseca, V. A., Grundy, S. M., Horton, E. S., Winter, M. L., Porte, D., Semenkovich, C. F., Smith, S. E., et al. (2003) · Circulation · doi:10.1161/01.cir.0000103683.99399.7e · Cited by 831
Cardiac remodeling in obesity
Abel, E. D., Litwin, S. E., & Sweeney, G. (2008) · Physiological Reviews · doi:10.1152/physrev.00017.2007 · Cited by 736
Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure
Nesto, R. W., Bell, D. S. H., Bonow, R. O., Fonseca, V. A., Grundy, S. M., Horton, E. S., Winter, M. L., Porte, D., Semenkovich, C. F., Smith, S. E., et al. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.256 · Cited by 585
Diabetic cardiomyopathy: Mechanisms and new treatment strategies targeting antioxidant signaling pathways
Huynh, K., Bernardo, B. C., McMullen, J. R., & Ritchie, R. H. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.01.003 · Cited by 556
Peroxisome Proliferator-Activated Receptors and Atherogenesis: Regulators of Gene Expression in Vascular Cells
Marx, N., Duez, H., Fruchart, J.-C., & Staels, B. (2004) · Circulation Research · doi:10.1161/01.res.0000127122.22685.0a · Cited by 501
Stress-hyperglycemia, insulin and immunomodulation in sepsis
Marik, P. E., & Raghavan, M. (2004) · Intensive Care Medicine · doi:10.1007/s00134-004-2167-y · Cited by 423
Peroxisome proliferator-activated receptors and inflammation
Moraes, L. A., Piqueras, L., & Bishop‐Bailey, D. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.08.007 · Cited by 381
Peroxisome Proliferator-Activated Receptors
Schiffrin, E. L., Amiri, F., Benkirane, K., Iglarz, M., & Diep, Q. N. (2003) · Hypertension · doi:10.1161/01.hyp.0000084370.74777.b6 · Cited by 370
Ligands of the peroxisome proliferator‐activated receptors (PPAR‐γ and PPAR‐α) reduce myocardial infarct size
Wayman, N. S., Hattori, Y., McDonald, M. C., Mota‐Filipe, H., Cuzzocrea, S., PISANO, B., Chatterjee, P. K., & Thiemermann, C. (2002) · The FASEB Journal · doi:10.1096/fj.01-0793com · Cited by 359
Oxidative stress and neutrophil activation--the two keystones of ischemia/reperfusion injury.
Kamiński, K., Bonda, T., Korecki, J., & Musiał, W. (2002) · International Journal of Cardiology · doi:10.1016/s0167-5273(02)00189-4 · Cited by 353
Safety issues and prospects for future generations of PPAR modulators
RUBENSTRUNK, A., HANF, R., HUM, D., FRUCHART, J., & STAELS, B. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.02.003 · Cited by 309
Modulation of the oxidative stress and inflammatory response by PPAR-γ agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion
Collino, M., Aragno, M., Mastrocola, R., Gallicchio, M., Rosa, A. C., Dianzani, C., Danni, O., Thiemermann, C., & Fantozzi, R. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.11.049 · Cited by 300
Healing after myocardial infarction
Ertl, G., & Frantz, S. (2005) · Cardiovascular Research · doi:10.1016/j.cardiores.2005.01.011 · Cited by 311
Age-Dependent Changes in Metabolism, Contractile Function, and Ischemic Sensitivity in Hearts From db/db Mice
Aasum, E., Hafstad, A. D., Severson, D. L., & Larsen, T. S. (2003) · Diabetes · doi:10.2337/diabetes.52.2.434 · Cited by 280
Thiazolidinediones in Type 2 Diabetes Mellitus
Diamant, M., & Heine, R. J. (2003) · Drugs · doi:10.2165/00003495-200363130-00004 · Cited by 281
Peroxisome proliferator-activated receptor-γ ligands reduce inflammation and infarction size in transient focal ischemia
Sundararajan, S., Gamboa, J. L., Victor, N., Wanderi, E. W., Lust, W. D., & Landreth, G. E. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.10.021 · Cited by 266
Pioglitazone, a Peroxisome Proliferator–Activated Receptor-γ Agonist, Attenuates Left Ventricular Remodeling and Failure After Experimental Myocardial Infarction
Shiomi, T., Tsutsui, H., Hayashidani, S., Suematsu, N., Ikeuchi, M., Wen, J., Ishibashi, M., Kubota, T., Egashira, K., & Takeshita, A. (2002) · Circulation · doi:10.1161/01.cir.0000039346.31538.2c · Cited by 256
The PPAR trio: Regulators of myocardial energy metabolism in health and disease
Madrazo, J., & Kelly, D. P. (2008) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2008.03.021 · Cited by 247
Involvement of PPAR nuclear receptors in tissue injury and wound repair
Michalik, L. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27958 · Cited by 243
Peroxisome proliferator-activated receptor γ (PPARγ): A master gatekeeper in CNS injury and repair
Cai, W., Yang, T., Liu, H., Han, L., Zhang, K., Hu, X., Zhang, X., Yin, K., Gao, Y., Bennett, M. V. L., et al. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.10.002 · Cited by 240
Self-citation
Brain protection by resveratrol and fenofibrate against stroke requires peroxisome proliferator-activated receptor α in mice
Inoue, H., Jiang, X., Katayama, T., Osada, S., Umesono, K., & Namura, S. (2003) · Neuroscience Letters · doi:10.1016/j.neulet.2003.09.001 · Cited by 238
Inhibition of Rho-kinase protects the heart against ischemia/reperfusion injury
Bao, W. (2004) · Cardiovascular Research · doi:10.1016/j.cardiores.2003.12.004 · Cited by 226
Self-citation
The PPAR regulatory system in cardiac physiology and disease
Finck, B. N. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2006.08.023 · Cited by 233
Beneficial effects of PPAR-? ligands in ischemia?reperfusion injury, inflammation and shock
Abdelrahman, M. S. I., Sivarajah, A., & Thiemermann, C. (2005) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.12.008 · Cited by 206
Neuroprotection against focal ischemic brain injury by the peroxisome proliferator‐activated receptor‐γ agonist rosiglitazone
Luo, Y., Yin, W., Signore, A. P., Zhang, F., Hong, Z., Wang, S., Graham, S. H., & Chen, J. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03758.x · Cited by 206
Self-citation
Activation of Peroxisome Proliferator–Activated Receptor-&agr; Protects the Heart From Ischemia/Reperfusion Injury
Yue, T., Bao, W., Jucker, B., Gu, J. L., Romanic, A., Brown, P., Cui, J.-Q., Thudium, D., Boyce, R., Burns-Kurtis, C. L., et al. (2003) · Circulation · doi:10.1161/01.cir.0000093187.42015.6c · Cited by 157
Self-citation
Rosiglitazone, a Peroxisome Proliferator-Activated Receptor-γ, Inhibits the Jun NH2-Terminal Kinase/Activating Protein 1 Pathway and Protects the Heart From Ischemia/Reperfusion Injury
Khandoudi, N., Delerive, P., Berrebi-Bertrand, I., Buckingham, R. E., Staels, B., & Bril, A. (2002) · Diabetes · doi:10.2337/diabetes.51.5.1507 · Cited by 174
Self-citation
Rosiglitazone
Wagstaff, A. J., & Goa, K. L. (2002) · Drugs · doi:10.2165/00003495-200262120-00007 · Cited by 175
Insulin says NO to cardiovascular disease
Yu, Q., Gao, F., & Ma, X. L. (2011) · Cardiovascular Research · doi:10.1093/cvr/cvq349 · Cited by 172
Rosiglitazone Treatment in Zucker Diabetic Fatty Rats Is Associated With Ameliorated Cardiac Insulin Resistance and Protection From Ischemia/Reperfusion-Induced Myocardial Injury
Yue, T.-L., Bao, W., Gu, J.-L., Cui, J., Tao, L., Ma, X.-L., Ohlstein, E. H., & Jucker, B. M. (2005) · Diabetes · doi:10.2337/diabetes.54.2.554 · Cited by 170
Self-citation
Minireview: Challenges and Opportunities in Development of PPAR Agonists
Wright, M. B., Bortolini, M., Tadayyon, M., & Bopst, M. (2014) · Molecular Endocrinology · doi:10.1210/me.2013-1427 · Cited by 172
Thiazolidinedione Treatment Normalizes Insulin Resistance and Ischemic Injury in the Zucker Fatty Rat Heart
Sidell, R. J., Cole, M. A., Draper, N. J., Desrois, M., Buckingham, R. E., & Clarke, K. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1110 · Cited by 165
Self-citation
Bacteria‐Derived Outer‐Membrane Vesicles Hitchhike Neutrophils to Enhance Ischemic Stroke Therapy
Pan, J., Wang, Z., Huang, X., Xue, J., Zhang, S., Guo, X., & Zhou, S. (2023) · Advanced Materials · doi:10.1002/adma.202301779 · Cited by 163
The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA
Ye, Y., Keyes, K. T., Zhang, C., Perez-Polo, J. R., Lin, Y., & Birnbaum, Y. (2010) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00867.2009 · Cited by 152
Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure
Tang, W. H. W., Francis, G. S., Hoogwerf, B. J., & Young, J. B. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00159-1 · Cited by 150
Angiotensin II Regulation of Collagen Type I Expression in Cardiac Fibroblasts
Chen, K., Chen, J., Li, D., Zhang, X., & Mehta, J. L. (2004) · Hypertension · doi:10.1161/01.hyp.0000144400.49062.6b · Cited by 152
Self-citation
Agonists of Peroxisome-Proliferator Activated Receptor-Gamma Reduce Renal Ischemia/Reperfusion Injury
Sivarajah, A., Chatterjee, P. K., Patel, N. S. A., Todorović, Z., Hattori, Y., Brown, P. A., Stewart, K. N., Mota‐Filipe, H., Cuzzocrea, S., & Thiemermann, C. (2003) · American Journal of Nephrology · doi:10.1159/000072088 · Cited by 144
Altered PPARγ expression and activation after transient focal ischemia in rats
Victor, N., Wanderi, E. W., Gamboa, J. L., Zhao, X., Aronowski, J. A., Deininger, K. M., Lust, W. D., Landreth, G. E., & Sundararajan, S. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05037.x · Cited by 143
Exercise Training Protects Against Acute Myocardial Infarction via Improving Myocardial Energy Metabolism and Mitochondrial Biogenesis
Tao, L., Bei, Y., Lin, S., Zhang, H., Zhou, Y., Jiang, J., Chen, P., Shen, S., Xiao, J., & Li, X. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000430342 · Cited by 135
Peroxisome-proliferator-activated receptors regulate redox signaling in the cardiovascular system
Kim, T. (2013) · World Journal of Cardiology · doi:10.4330/wjc.v5.i6.164 · Cited by 133
Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease
Robinson, E., & Grieve, D. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.03.003 · Cited by 132
15d-Prostaglandin J 2 Protects Brain From Ischemia-Reperfusion Injury
Lin, T., Cheung, W.-M., Wu, J., Chen, J.-J., Lin, H., Chen, J.-J., Liou, J., Shyue, S., & Wu, K. K. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000201933.53964.5b · Cited by 127
Self-citation
Peroxisome proliferator-activated receptors: a critical review on endogenous pathways for ligand generation
Bishop‐Bailey, D., & Wray, J. A. (2003) · Prostaglandins & Other Lipid Mediators · doi:10.1016/s0090-6980(03)00003-0 · Cited by 131
Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion.
Liu, H.-R., Tao, L., Gao, E., Lopez, B., Christopher, T., Willette, R., Ohlstein, E., Yue, T., & Ma, X.-L. (2004) · Cardiovascular Research · doi:10.1016/j.cardiores.2003.12.027 · Cited by 131
Peroxisome proliferator-activated receptor δ activates fatty acid oxidation in cultured neonatal and adult cardiomyocytes
Cheng, L., Ding, G., Qin, Q., Xiao, Y., Woods, D., Chen, Y. E., & Yang, Q. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.11.127 · Cited by 121
Pioglitazone Inhibits LOX-1 Expression in Human Coronary Artery Endothelial Cells by Reducing Intracellular Superoxide Radical Generation
Mehta, J. L., Hu, B., Chen, J., & Li, D. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000094411.98127.5f · Cited by 121
Self-citation
Angiotensin II Type 1 Receptor–Mediated Inflammation Is Required for Choroidal Neovascularization
Nagai, N., Oike, Y., Izumi‐Nagai, K., Urano, T., Kubota, Y., Noda, K., Ozawa, Y., Inoue, M., Tsubota, K., Suda, T., et al. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000240050.15321.fe · Cited by 122
Peroxisome proliferator-activated receptor gamma as a drug target in the pathogenesis of insulin resistance
Guo, L., & Tabrizchi, R. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.10.009 · Cited by 117
The Hinge-Helix 1 Region of Peroxisome Proliferator-Activated Receptor γ1 (PPARγ1) Mediates Interaction with Extracellular Signal-Regulated Kinase 5 and PPARγ1 Transcriptional Activation: Involvement in Flow-Induced PPARγ Activation in Endothelial Cells
Akaike, M., Che, W., Marmarosh, N.-L., Ohta, S., Osawa, M., Ding, B., Berk, B. C., Chen, Y., & Abe, J. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.19.8691-8704.2004 · Cited by 115
Adiponectin Is Required for PPARγ-Mediated Improvement of Endothelial Function in Diabetic Mice
Wong, W. T., Tian, X. Y., Xu, A., Yu, J. Q., Lau, C. W., Hoo, R. L. C., Wang, Y., Lee, V. W. Y., Lam, K. S. L., Vanhoutte, P. M., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.05.009 · Cited by 115
Ligand-Activated Peroxisome Proliferator–Activated Receptor-γ Protects Against Ischemic Cerebral Infarction and Neuronal Apoptosis by 14-3-3ε Upregulation
Wu, J., Cheung, W.-M., Tsai, Y.-S., Chen, Y.-T., Fong, W.-H., Tsai, H.-D., Chen, Y., Liou, J., Shyue, S., Chen, J.-J., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.812537 · Cited by 114
Self-citation
Inhibition of NF-kappaB signaling by fenofibrate, a peroxisome proliferator-activated receptor-alpha ligand, presents a therapeutic strategy for rheumatoid arthritis.
Okamoto, H., Iwamoto, T., Kotake, S., Momohara, S., Yamanaka, H., & Kamatani, N. (2005) · PubMed · Cited by 113
Peroxisome proliferator-activated receptors and cardiovascular remodeling
Schiffrin, E. L. (2004) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00677.2004 · Cited by 110
Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases?
Becker, J., Delayre‐Orthez, C., Frossard, N., & Pons, F. (2006) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2006.00425.x · Cited by 109
Roles of PPARs on regulating myocardial energy and lipid homeostasis
Yang, Q., & Li, Y. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0170-9 · Cited by 106
PPARγ as a therapeutic target in central nervous system diseases
Sundararajan, S. S., Jiang, Q., Heneka, M. T., & Landreth, G. E. (2006) · Neurochemistry International · doi:10.1016/j.neuint.2006.03.020 · Cited by 112
The effects of PPAR-? ligand pioglitazone on platelet aggregation and arterial thrombus formation
LI, D., CHEN, K., SINHA, N., ZHANG, X., Wang, Y., SINHA, A., Romeo, F., & Mehta, J. L. (2004) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.11.027 · Cited by 105
Pioglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, Attenuates Myocardial Ischemia/Reperfusion Injury in a Rat Model
Ito, H., Nakano, A., Kinoshita, M., & Matsumori, A. (2003) · Laboratory Investigation · doi:10.1097/01.lab.0000106724.29121.da · Cited by 104
15-Deoxy-Δ12,14-prostaglandin J2-induced apoptosis does not require PPARγ in breast cancer cells
Clay, C. E., Monjazeb, A., Thorburn, J., Chilton, F. H., & High, K. P. (2002) · Journal of Lipid Research · doi:10.1194/jlr.m200224-jlr200 · Cited by 103
The potential effects of anti-diabetic medications on myocardial ischemia–reperfusion injury
Ye, Y., Perez-Polo, J. R., Aguilar, D. A., & Birnbaum, Y. (2011) · Basic Research in Cardiology · doi:10.1007/s00395-011-0216-6 · Cited by 101
Current perspective of pathophysiological and interventional effects on endothelial progenitor cell biology: Focus on Pi3K/AKT/eNOS pathway
Everaert, B., Craenenbroeck, E. M. V., Hoymans, V. Y., Haine, S. E. F., Nassauw, L. V., Conraads, V. M., Timmermans, J., & Vrints, C. J. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2010.04.018 · Cited by 100
Expression of Concern: Rosiglitazone and 15‐deoxy‐Δ12,14‐prostaglandin J2, ligands of the peroxisome proliferator‐activated receptor‐γ (PPAR‐γ), reduce ischaemia/reperfusion injury of the gut
Cuzzocrea, S., Pisano, B., Dugo, L., Ianaro, A., Patel, N. S. A., Paola, R. D., Genovese, T., Chatterjee, P. K., Rosa, M. D., Caputi, A. P., et al. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705419 · Cited by 97
Cardiac substrate uptake and metabolism in obesity and type-2 diabetes: Role of sarcolemmal substrate transporters
Coort, S. L., Bonen, A., Vusse, G. J., Glatz, J. F. C., & Luiken, J. J. F. P. (2006) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-005-9030-5 · Cited by 100
Rosiglitazone and PPAR‐γ overexpression protect mitochondrial membrane potential and prevent apoptosis by upregulating anti‐apoptotic Bcl‐2 family proteins
Wu, J., Lin, T., & Wu, K. K. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21730 · Cited by 98
Rosiglitazone Improves Myocardial Glucose Uptake in Patients With Type 2 Diabetes and Coronary Artery Disease
Läutamaki, R., Airaksinen, J. K. E., Seppänen, M., Toikka, J., Luotolahti, M., Ball, E., Borra, R., Härkönen, R., Iozzo, P., Stewart, M. W., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.9.2787 · Cited by 98
Rosiglitazone Reduces the Development and Rupture of Experimental Aortic Aneurysms
Jones, A., Deb, R., Torsney, E., Howe, F. A., Dunkley, M., Gnaneswaran, Y., Gaze, D. C., Nasr, H. H., Loftus, I. M., Thompson, M. M., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.852467 · Cited by 101
Are targeted therapies for diabetic cardiomyopathy on the horizon?
Tate, M., Grieve, D., & Ritchie, R. H. (2017) · Clinical Science · doi:10.1042/cs20160491 · Cited by 96
Myocardial Glucose Transport and Utilization in Patients With Type 2 Diabetes Mellitus, Left Ventricular Dysfunction, and Coronary Artery Disease
Dutka, D. P., Pitt, M., Pagano, D., Mongillo, M., Gathercole, D., Bonser, R. S., & Camici, P. G. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.06.078 · Cited by 96
Glitazones and Heart Failure
Wang, C., Weisel, R. D., Liu, P. P., Fedak, P. W. M., & Verma, S. (2003) · Circulation · doi:10.1161/01.cir.0000054675.30348.9a · Cited by 94
Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, protects against gastric ischemia–reperfusion damage in rats: role of oxygen free radicals generation
Villegas, I., Martín, A. R., Toma, W., & Alarcón‐de‐la‐Lastra, C. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.10.020 · Cited by 93
Cortical Neurons Develop Insulin Resistance and Blunted Akt Signaling: A Potential Mechanism Contributing to Enhanced Ischemic Injury in Diabetes
Kim, B., Sullivan, K. A., Backus, C., & Feldman, E. L. (2011) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3816 · Cited by 93
Peroxisome Proliferator-Activated Receptors and the Heart: Lessons from the Past and Future Directions
Lee, W. S., & Kim, J. (2015) · PPAR Research · doi:10.1155/2015/271983 · Cited by 97
Peroxisome proliferator-activated receptor-γ-agonist, rosiglitazone, promotes angiogenesis after focal cerebral ischemia
Chu, K., Lee, S., Koo, J.-S., Jung, K., Kim, E., Sinn, D.-I., Kim, J., Ko, S., Kim, S., Song, E.-C., et al. (2006) · Brain Research · doi:10.1016/j.brainres.2006.03.114 · Cited by 87
Mechanical Stretch Induces Monocyte Chemoattractant Activity via an NF-κB-Dependent Monocyte Chemoattractant Protein-1-Mediated Pathway in Human Mesangial Cells
Gruden, G., Setti, G., Hayward, A. E., Sugden, D., Duggan, S., Burt, D. J., Buckingham, R. E., Gnudi, L., & Viberti, G. C. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004030251 · Cited by 89
Self-citation
The PPARγ-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction
Lygate, C. A. (2003) · Cardiovascular Research · doi:10.1016/s0008-6363(03)00289-x · Cited by 89
Anti-apoptotic Actions of PPAR-γ Against Ischemic Stroke
Fong, W.-H., Tsai, H., Chen, Y.-C., Wu, J., & Lin, T. (2010) · Molecular Neurobiology · doi:10.1007/s12035-010-8103-y · Cited by 87
Review: PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury
Collino, M., Patel, N. S. A., & Thiemermann, C. (2008) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944708090924 · Cited by 87
Acute rosiglitazone treatment is cardioprotective against ischemia-reperfusion injury by modulating AMPK, Akt, and JNK signaling in nondiabetic mice
Morrison, A., Yan, X., Tong, C., & Li, J. (2011) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00137.2011 · Cited by 87
PPAR‐γ Activator Pioglitazone Prevents Age‐Related Atrial Fibrillation Susceptibility by Improving Antioxidant Capacity and Reducing Apoptosis in a Rat Model
Xu, D., Murakoshi, N., Igarashi, M., Hirayama, A., Ito, Y., Seo, Y., Tada, H., & Aonuma, K. (2011) · Journal of Cardiovascular Electrophysiology · doi:10.1111/j.1540-8167.2011.02186.x · Cited by 85
Peroxisome proliferator-activated receptor-?: therapeutic target for diseases beyond diabetes: quo vadis?
Pershadsingh, H. A. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.3.215 · Cited by 83
Atherosclerosis in type 2 diabetes mellitus and insulin resistance: mechanistic links and therapeutic targets
Plutzky, J., Viberti, G. C., & Haffner, S. M. (2002) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(02)00202-7 · Cited by 81
Peroxisome Proliferator-Activated Receptor .GAMMA. and Cardiovascular Diseases
Takano, H., & Komuro, I. (2009) · Circulation Journal · doi:10.1253/circj.cj-08-1071 · Cited by 79
Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?
Patel, C. B., Wyne, K. L., & McGuire, D. K. (2005) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2005.010 · Cited by 78
Pioglitazone ameliorates endothelial dysfunction and restores ischemia-induced angiogenesis in diabetic mice
Huang, P., Sata, M., Nishimatsu, H., Sumi, M., Hirata, Y., & Nagai, R. (2007) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2007.06.014 · Cited by 76
PPAR-γ and AMPK – Advantageous targets for myocardial ischemia/reperfusion therapy
Morrison, A., & Li, J. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.04.004 · Cited by 75
The cyclopentenone prostaglandin 15-deoxy-Δ12,14-prostaglandin J2 ameliorates ischemic acute renal failure
Chatterjee, P. K. (2003) · Cardiovascular Research · doi:10.1016/j.cardiores.2003.10.024 · Cited by 73
Myocardial protection by pioglitazone, atorvastatin, and their combination: mechanisms and possible interactions
Ye, Y., Lin, Y., Atar, S., Huang, M.-H., Perez-Polo, J. R., Uretsky, B. F., & Birnbaum, Y. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00096.2006 · Cited by 74
Combined Thiazolidinedione-Insulin Therapy
Scheen, A. J. (2004) · Drug Safety · doi:10.2165/00002018-200427120-00002 · Cited by 73
Rosiglitazone Reduces Insulin Requirement and C-Reactive Protein Levels in Type 2 Diabetic Patients Receiving Peritoneal Dialysis
Wong, T. Y.-H., Szeto, C., Chow, K., Leung, C. B., Lam, C. W.-K., & Li, P. K. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.06.020 · Cited by 72
Cardioprotective effects of rosiglitazone are associated with selective overexpression of type 2 angiotensin receptors and inhibition of p42/44 MAPK
Molavi, B., Chen, J., & Mehta, J. L. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00926.2005 · Cited by 72
Self-citation
Thiazolidinediones ? some recent developments
Stümvoll, M. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.7.1179 · Cited by 71
In Vivo Activation of Peroxisome Proliferator-Activated Receptor-δ Protects the Heart from Ischemia/Reperfusion Injury in Zucker Fatty Rats
Yue, T., Nerurkar, S. S., Bao, W., Jucker, B. M., Sarov‐Blat, L., Steplewski, K. M., Ohlstein, E. H., & Willette, R. N. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.135327 · Cited by 68
Self-citation
PPARs as therapeutic targets in cardiovascular disease
van Bilsen, M., & van Nieuwenhoven, F. A. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2010.512917 · Cited by 67
Cardioprotection mediated by rosiglitazone, a peroxisome proliferatoractivated receptor gamma ligand, in relation to nitric oxide
Gonon, A. T., Bulhak, A., Labruto, F., Sjöquist, P.-O. B., & Pernow, J. (2006) · Basic Research in Cardiology · doi:10.1007/s00395-006-0613-4 · Cited by 67
PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertainty
Huang, J. V., Greyson, C. R., & Schwartz, G. G. (2012) · Journal of Lipid Research · doi:10.1194/jlr.r024505 · Cited by 68
PPARs of the Heart
Kelly, D. P. (2003) · Circulation Research · doi:10.1161/01.res.0000064382.46274.95 · Cited by 66

Authors: Yue, T.-L., Chen, J., Bao, W., Narayanan, P. K., Bril, A., Jiang, W., Lysko, P. G., Gu, J.-L., Boyce, R., Zimmerman, D. M., Hart, T. K., Buckingham, R. E., & Ohlstein, E. H.
Affiliations: From the Departments of Cardiovascular Pharmacology (T.Y., J.C., W.B., A.B., W.J., P.G.L., J.G., R.E.B., E.H.O.) and Safety Assessment (P.K.N., R.B., D.M.Z., T.K.H.), GlaxoSmithKline Pharmaceuticals, King of Prussia, Pa.
GlaxoSmithKline (United States) (US)
GlaxoSmithKline (United Kingdom) (GB)
ORCID: Bao, Weike
Bril, Antoine
Jiang, Wen
Boyce, Rogely
Zimmerman, Dawn M.
Venue: Circulation
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2001-11-20
Volume: 104
Issue: 21
Pages: 2588-2594
ISSN: 0009-7322 (ISSN-L)
1524-4539
DOI: 10.1161/hc4601.099403
OpenAlex: W2102772338
Cited by: 295
References: 32
Citations by year: 2026: 2 · 2025: 3 · 2024: 2 · 2023: 5 · 2022: 3 · 2021: 3 · 2020: 6 · 2018: 5 · 2017: 5 · 2016: 4 · 2015: 9 · 2014: 9 · 2013: 11 · 2012: 14
FWCI: 17.41
Type: journal article
Language: en
Open access: closed
Locations: Circulation (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Ischemia and Reperfusion
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
Keywords: rosiglitazone, PPARγ agonists, myocardial ischemia-reperfusion injury, myocardial infarction, cardioprotection, infarct size, myocardial contractile dysfunction, neutrophil accumulation, macrophage accumulation, leukocyte adhesion molecules, CD11b/CD18, L-selectin, ICAM-1, MCP-1, inflammation, diabetes mellitus, acute myocardial infarction
MeSH terms: Rosiglitazone, Animals, Hypoglycemic Agents, Macrophages, Male, Monocytes, Myocardial Contraction, Myocardial Infarction, Neutrophils, Rats, Inbred Lew, RNA, Messenger, Thiazoles, Transcription Factors, Myocardial Reperfusion Injury, Cell Adhesion Molecules, Macrophage-1 Antigen, Receptors, Cytoplasmic and Nuclear, CD18 Antigens, Chemokine CCL2, Neutrophil Infiltration, Thiazolidinediones, Diabetes Complications, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

In Vivo Myocardial Protection From Ischemia/Reperfusion Injury by the Peroxisome Proliferator–Activated Receptor-γ Agonist Rosiglitazone

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks